Relamorelin (INN, USAN) (developmental code names RM-131, BIM-28131, BIM-28163) is a synthetic peptide, centrally penetrant, selective agonist of the ghrelin/growth hormone secretagogue receptor (GHSR) which is under development by Allergan pharmaceuticals for the treatment of diabetic gastroparesis, chronic idiopathic constipation, and anorexia nervosa.

[1][2][3] It is a pentapeptide and an analogue of ghrelin with improved potency and pharmacokinetics.

[3] As of June 2015, relamorelin is in phase II clinical trials for diabetic gastroparesis and constipation.

[5] The United States Food and Drug Administration (FDA) has granted Fast Track designation to relamorelin for diabetic gastroparesis.

You can help Wikipedia by expanding it.This drug article relating to the gastrointestinal system is a stub.